title: Effect of PPAR-γ agonist rosiglitazone on bone mineral density and serum adipokines in C57BL/6 male mice.
abstract: Thiazolinediones (TZD) are widely used to             treat type 2 diabetes, but their mechanism of action             still remains only partially understood. Although the             in vitro effects of TZD on osteoblastogenesis are well             recognized, the in vivo consequences of these compounds             on bone turnover are less understood and             rather controversial. We demonstrate that a 9-week             oral treatment with rosiglitazone in C57BL/6 male             mice resulted in significant bone loss that was not             dose dependent. The bones of the rosiglitazone-treated             mice were characterized by reduction of bone             density, and ash, calcium and phosphorus content.             Rosiglitazone-treated mice had significantly thinner             cortical widths. In contrast to serum TrACP expressed             by action of osteoclasts, serum B-ALP activity,             which serves as a marker of osteoblastic activity,             was significantly lower in the rosiglitazone-fed animals.             We did not find any differences in circulating             levels of adipokines that could eventually explain             rosiglitazone action. As the decrease in osteoblastic             activity was demonstrated after rosiglitazone treatment,             we anticipated changes in the haematopoietic stem cell pool.              These cells seed in endosteal niches             which comprise osteoblasts in order to maintain             their stem cell function. In our study we did not see             any significant influence of rosiglitazone administration             on stem cells or any impairment in the lineage             restrictions of rosiglitazone-treated stem cells. Our             data demonstrate that rosiglitazone administration             causes a loss of bone mass in cortical bone, possibly             through a decrease in bone formation expressed by             decreased B-ALP in male C57BL/6 mice. The levels             of adipokines do not play any role.
authors: Third Department of Medicine - Department of Endocrinology and Metabolism, Charles University in Prague, Czech Republic. pbrou@lf1.cuni.cz
authors: P D
authors: PD
authors: Broulík
authors: L
authors: L
authors: Sefc
authors: M
authors: M
authors: Haluzík
mesh_terms: D054392:Adipokines / Q000378:metabolism; D000469:Alkaline Phosphatase / Q000378:metabolism; D000818:Animals; D015519:Bone Density / Q000187:drug effects*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D047495:PPAR gamma / Q000819:agonists*; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000494:pharmacology*
chemical_list: D054392:Adipokines; D047495:PPAR gamma; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D000469:Alkaline Phosphatase